Evidence map›Paper›PMID 30213827›Full record

ArticleHaematologica2019

Bianca Schuhmacher, Julia Bein, Tobias Rausch, Vladimir Benes, Thomas Tousseyn, Martine Vornanen, Maurilio Ponzoni, Lorenz Thurner, Randy Gascoyne, Christian Steidl and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. 3D analyses reveal T cells with activated nuclear features in T-cell/histiocyte-rich large B-cell lymphoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 5 countries.

Bianca SchuhmacherDr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.
Julia BeinDr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.
Tobias RauschGenecore, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Vladimir BenesGenecore, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Thomas TousseynDepartment of Pathology, University Hospitals K.U. Leuven, Belgium.
Martine VornanenDepartment of Pathology, Tampere University Hospital and University of Tampere, Finland.
Maurilio PonzoniUnit of Lymphoid Malignancies, Department of Pathology, Scientific Institute San Raffaele, Milan, Italy.
Lorenz ThurnerJosé Carreras Center for Immuno and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg, Saar, Germany.
Randy GascoyneDepartment of Pathology and Laboratory Medicine and the Centre for Lymphoid Cancer, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
Christian SteidlDepartment of Pathology and Laboratory Medicine and the Centre for Lymphoid Cancer, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
Ralf KüppersInstitute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
Martin-Leo HansmannDr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany.
Sylvia HartmannDr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany s.hartmann@em.uni-frankfurt.de.
Goethe University Frankfurt · DEEuropean Molecular Biology Laboratory · DEBC Cancer Agency · CADeutschen Konsortium für Translationale Krebsforschung · DEFrankfurt Institute for Advanced Studies · DEKU Leuven · BESaarland University · DESan Raffaele University of Rome · ITTampere University · FIUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell/histiocyte-rich large B-cell lymphoma is a rare aggressive lymphoma showing histopathological overlap with nodular lymphocyte-predominant Hodgkin lymphoma. Despite differences in tumor microenvironment and clinical behavior, the tumor cells of both entities show remarkable similarities, suggesting that both lymphomas might represent a spectrum of the same disease. To address this issue, we investigated whether these entities share mutations. Ultra-deep targeted resequencing of six typical and 11 histopathological variants of nodular lymphocyte-predominant Hodgkin lymphoma, and nine cases of T-cell/histiocyte-rich large B-cell lymphoma revealed that genes recurrently mutated in nodular lymphocyte-predominant Hodgkin lymphoma are affected by mutations at similar frequencies in T-cell/histiocyte-rich large B-cell lymphoma. The most recurrently mutated genes were

Indexed as

Biomarkers, TumorMutationAdultAgedAged, 80 and overCREB-Binding ProteinDual Specificity Phosphatase 2FemaleHistiocytesHumansImmediate-Early ProteinsLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMutation RateProtein Serine-Threonine KinasesBiomarkers, TumorCREB-Binding ProteinCREBBP protein, humanDual Specificity Phosphatase 2DUSP2 protein, humanImmediate-Early ProteinsJunB protein, humanProtein Serine-Threonine KinasesSerum-Glucocorticoid Regulated KinasesSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinTranscription Factors

Identifiers

PMID30213827
PMCPMC6355500
OpenAlexW2892342442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.